The upcoming AI in Clinical Development Summit aims to unite leaders in life sciences and technology to discuss the real-world applications of AI in clinical trials.
Scheduled for May 27, 2026, in New York City, the summit will feature prominent figures from major pharmaceutical companies such as AstraZeneca, Bristol Myers Squibb, Sanofi, and Roche, alongside technology experts from firms like Accenture and AWS. The event will include a range of activities, including expert panels, fireside chats, and workshops designed to provide actionable insights for attendees.
Key topics will focus on accelerating trial timelines, transitioning from pilot projects to full-scale AI integration, and enhancing decision-making processes. Orr Inbar, CEO of QuantHealth, emphasized that the narrative around AI has evolved from speculation to tangible implementation, highlighting the importance of measuring AI's impact in clinical trials.
This summit, now in its third year, has established itself as a critical platform for leaders in the life sciences sector, aiming to leverage AI for improved clinical outcomes and faster delivery of therapies. It serves as an invitation-only event, reflecting its exclusivity and the high caliber of participants, which includes representatives from 18 of the top 20 pharmaceutical companies.